natgillin/translations-raw huggingface dataset:
Population pharmacokinetic analyses did not detect any effect of methotrexate, NSAIDs, and corticosteroids on abatacept clearance (see section 5.2). 
Pri analizah populacijske farmakokinetike učinkov metotreksata, nesteroidnih protivnetnih zdravil in kortikosteroidov na očistek abatacepta niso odkrili (glejte poglavje 5.2).
Studies I, II, III, V, and VI required patients to have at least 12 tender and 10 swollen joints at randomisation. 
V študije I, II, III, V in VI so bili vključeni bolniki, ki so ob randomizaciji imeli vsaj 12 občutljivih in 10 oteklih sklepov.
Parenteral medicinal products containing maltose can interfere with the readings of blood glucose monitors that use test strips with glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ). 
Zdravila za parenteralno uporabo, ki vsebujejo maltozo, lahko vplivajo na odčitke merjenja koncentracije krvnega sladkorja pri uporabi testnih lističev z glukoza dehidrogenaza pirolokinolinkinonom (GDH-PQQ).
Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis or pJIA. 
Zdravljenje mora uvesti in nadzirati zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa ali pJIA.
Check the liquid through the viewing window. 
Preverite tekočino preko nadzornega okenca.
The most frequently reported event with abatacept (1-2%) was dizziness. 
Pri bolnikih, ki so prejemali abatacept, so najpogosteje (1-2 %) poročali o omotici.
There is a theoretical concern that treatment with abatacept might increase the risk for autoimmune processes in adults, for example deterioration of multiple sclerosis. 
Teoretično se pri zdravljenju z abataceptom lahko poveča tveganje za avtoimunske procese pri odraslih, na primer poslabšanje multiple skleroze.
Needle Cover (ORANGE Cap) 
Pokrovček igle (ORANŽNA zaporka)
Structural joint damage was assessed radiographically over a two-year period in studies II, and VI. 
Strukturne poškodbe sklepa so vrednotili radiološko med dveletnim obdobjem v študiji II in v študiji VI.
A single study was conducted to determine the effect of monotherapy use of abatacept on immunogenicity following subcutaneous administration without an intravenous load. 
Izvedena je bila ena študija za določitev učinka monoterapije z abataceptom na imunogenost po subkutani uporabi brez začetnega intravenskega odmerka.
In Period A all patients received 10 mg/kg of abatacept on days 1, 15, 29, 57 and 85 and were assessed on day 113. 
V obdobju A so vsi bolniki prejeli abatacept v odmerku 10 mg/kg na 1., 15., 29., 57. in 85. dan in so bili nato ovrednoteni na 113. dan.
Talk to your doctor, pharmacist or nurse: if you experience allergic reactions such as chest tightness, wheezing, severe dizziness or lightheadedness, swelling or skin rash tell your doctor immediately. 
Posvetujte se z zdravnikom, farmacevtom ali medicinsko sestro: če se pojavijo znaki alergijske reakcije, kot so stiskanje v prsih, težko dihanje, huda omotica ali vrtoglavica, oteklina ali kožni izpuščaj, to nemudoma povejte svojemu zdravniku.
Subjects continued taking their current dose of MTX from the day of randomisation. 
Bolniki so od dneva randomizacije nadaljevali zdravljenje z MTX v trenutnem odmerku.
There were six overall discontinuations during this period, only one of which was due to an AE (the SAE of post-operative wound infection). 
V celoti je bilo v tem obdobju iz študije izključenih 6 bolnikov, od tega le eden zaradi neželenega učinka (resen neželeni učinek pooperativne okužbe rane).
Women of childbearing potential have to use effective contraception during treatment and up to 14 weeks after the last dose of abatacept. 
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem in do 14 tednov po prejemu zadnjega odmerka abatacepta.
In SC-III the safety profiles of the three treatment groups (abatacept + MTX, abatacept monotherapy, MTX group) were overall similar. 
V študiji SC-III so bili profili varnosti v treh skupinah zdravljenja (abatacept + MTX, monoterapija z abataceptom, skupina z MTX) na splošno podobni.
This means that before ORENCIA is given to you, it is first dissolved in water for injections, then further diluted with sodium chloride 9 mg/mL (0.9%) solution for injection. 
To pomeni, da bodo zdravilo ORENCIA preden ga boste prejeli, najprej raztopili v vodi za injekcije in nato še nadalje razredčili z 0,9% raztopino natrijevega klorida za injekcije (9 mg/ml).
If you stop using ORENCIA The decision to stop using ORENCIA should be discussed with your doctor. 
Če ste prenehali uporabljati zdravilo ORENCIA O prekinitvi zdravljenja z zdravilom ORENCIA se morate posvetovati s svojim zdravnikom.
Vial (15 mL Type 1 glass) with a stopper (halobutyl-rubber) and flip off seal (aluminium). 
Viala (15 ml iz stekla tipa 1) z zamaškom (halobutilna guma) in dvižno zaporko (aluminij).
Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis. 
Zdravljenje mora uvesti in nadzirati zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa.
Step 3: Check the Dose on the Pre-filled Syringe Hold the syringe at eye level. 
3. korak: Preverite odmerek v napolnjeni injekcijski brizgi Injekcijsko brizgo držite v višini oči.
EU/1/07/389/002 2 vials and 2 silicone-free syringes (2 packs of 1) EU/1/07/389/003 3 vials and 3 silicone-free syringes (3 packs of 1) 
EU/1/07/389/002 2 viali in 2 injekcijski brizgi brez silikona (2 pakiranji po 1) EU/1/07/389/003 3 viale in 3 injekcijske brizge brez silikona (3 pakiranja po 1)
c Patients who had less than 20% improvement in tender or swollen joint counts at Week 16 met escape criteria and were considered non-responders. 
c Bolniki, pri katerih se število občutljivih ali oteklih sklepov v 16. tednu ni zmanjšalo vsaj za 20%, so izpolnili kriterije za izključitev in so bili obravnavani kot bolniki brez odziva.
Doses up to 50 mg/kg have been administered intravenously without apparent toxic effect. 
Uporabljeni so bili intravenski odmerki do 50 mg/kg brez očitnih toksičnih učinkov.
If you received ORENCIA during your pregnancy, your baby may have a higher risk for getting an infection. 
Če ste zdravilo ORENCIA prejeli med nosečnostjo, se pri otroku lahko poveča tveganje za pojav okužbe.
Abatacept decreases antigen specific TNFα, interferon-γ, and interleukin-2 production by T lymphocytes. 
Abatacept zmanjša T limfocitno produkcijo antigensko specifičnega TNFα, interferona-γ in interlevkina-2.
The presence of antibodies was not associated with adverse reactions or infusion reactions, or with changes in efficacy or serum abatacept concentrations. 
Prisotnost protiteles ni bila povezana niti s pojavom neželenih učinkov ali infuzijskih reakcij niti s spremembami učinkovitosti ali spremembami v serumskih koncentracijah abatacepta.
ORENCIA should not be infused concomitantly in the same intravenous line with other medicinal products. 
Zdravila ORENCIA se ne sme infundirati sočasno z drugimi zdravili preko iste intravenske linije.
If needed, you may apply a small adhesive plaster to the injection site. 
Po potrebi lahko na mesto injiciranja namestite manjši samolepilni obliž.
The patients entered in the trial were a mean of 12.4 years of age with mean disease duration of 4.4 years. 
Bolniki, ki so bili vključeni v preskušanje, so bili v povprečju stari 12,4 let, bolezen pa je v povprečju trajala 4,4 leta.
Following the initial administration, ORENCIA should be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter. 
Po začetni aplikaciji mora bolnik zdravilo ORENCIA prejeti 2 in 4 tedne po prvem infundiranju, nato pa na vsake 4 tedne.
Mean steady-state trough concentrations were approximately 25 mcg/mL, and mean Cmax concentrations were approximately 290 mcg/mL. 
Povprečne najmanjše koncentracije v stanju dinamičnega ravnovesja so bile približno 25 μg/ml, povprečne Cmax koncentracije pa približno 290 μg/ml.
Combination with TNF-inhibitors 
Kombinacija z zaviralci TNF
Inspect the syringe for obvious flaws, but don't remove the needle cover. 
Preverite, če je injekcijska brizga kakor koli očitno poškodovana, vendar pa pri tem pokrovčka igle ne smete odstraniti.
The recommended dose of abatacept for adults with rheumatoid arthritis or psoriatic arthritis is based on body weight: 
Priporočeni odmerek abatacepta za odrasle z revmatoidnim artritisom ali s psoriaznim artritisom je odvisen od telesne mase:
If you miss your dose by more than three days, ask your doctor when to take your next dose. 
Če ste izpustili odmerek za več kot tri dni, se o uporabi naslednjega odmerka posvetujte s svojim zdravnikom.
No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of ORENCIA with other medicines. 
Študije fizikalne in biokemične stabilnosti pri sočasni aplikaciji zdravila ORENCIA in drugih zdravil niso bile izvedene.
For children and adolescents aged 6 to 17 years with polyarticular juvenile idiopathic arthritis who weigh less than 75 kg, the recommended dose of intravenous abatacept is 10 mg/kg. 
Za otroke in mladostnike, stare od 6 do 17 let, s poliartikularnim juvenilnim idiopatskim artritisom s telesno maso, manjšo od 75 kg, je priporočeni intravenski odmerek abatacepta 10 mg/kg.
Abatacept is produced by recombinant DNA technology in Chinese hamster ovary cells. 
Abatacept je pridobljen s tehnologijo rekombinantne DNA na ovarijskih celicah kitajskega hrčka.
However, if you are feeling tired or unwell after receiving ORENCIA, you should not drive, cycle or operate any machinery. 
Kljub temu pa v primeru, da se po prejemu zdravila ORENCIA počutite utrujeni ali se slabo počutite, ne smete voziti vozil, kolesariti ali upravljati strojev.
Clinical responses in controlled trials Percent of patients 
Preglednica 3: Klinični odzivi v nadzorovanih preskušanjih Odstotek bolnikov
Abatacept is a fusion protein produced by recombinant DNA technology in Chinese hamster ovary cells. 
Abatacept je fuzijski protein, pridobljen s tehnologijo rekombinantne DNA na ovarijskih celicah kitajskega hrčka.
In those patients who initially received infliximab and then switched to abatacept, the reduction in the mean DAS28 score from baseline was 3.29 at day 729 and 2.48 at day 365. 
Pri bolnikih, ki so v začetku prejemali infliksimab in so nato prešli na zdravljenje z abataceptom, je zmanjšanje povprečne vrednosti DAS28 od izhodišča na 729. dan znašalo 3,29, na 365. dan pa 2,48.
You will hear a click as the injection begins. 
Ob začetku injiciranja boste zaslišali klik.
Summary of the safety profile in psoriatic arthritis 
Povzetek varnostnega profila pri psoriaznem artritisu
It is recommended that patients with juvenile idiopathic arthritis be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating ORENCIA therapy (see section 4.5). 
Pri bolnikih z juvenilnim idiopatskim artritisom je pred uvedbo zdravljenja z zdravilom ORENCIA priporočljivo opraviti vsa priporočena cepljenja v skladu s trenutno veljavnimi smernicami za cepljenje (glejte poglavje 4.5).
Front of thighs 
Prednji del stegen
At 24 months, 50.6% (127/251) [95% CI: 44.4, 56.8] of patients in abatacept and 53.3% (130/244) [95% CI: 47.0, 59.5] of patients in adalimumab groups achieved DAS 28 < 2.6. 
Po 24 mesecih je 50,6 % (127/251) [95 % IZ: 44,4; 56,8] bolnikov v skupini z abataceptom in 53,3 % (130/244) [95 % IZ: 47,0; 59,5] bolnikov v skupini z adalimumabom doseglo DAS 28 < 2,6.
Keep any remaining unused syringes in their original carton, in the refrigerator. 
Preostale, še neuporabljene napolnjene injekcijske brizge pustite v hladilniku v originalni ovojnini.
Flare was defined as: ≥ 30% worsening in at least 3 of the 6 pJIA core set variables ≥ 30% improvement in not more than 1 of the 6 pJIA core set variables ≥ 2 cm (possible up to 10 cm) of worsening must have been present if the Physician or Parent Global Assessment was used to define flare worsening in ≥ 2 joints must have been present if the number of active joints or joints with limited range of motion was used to define flare 
Poslabšanje je bilo definirano kot: ≥ 30% poslabšanje pri vsaj 3 od 6 ključnih spremenljivk pJIA ≥ 30% izboljšanje pri ne več kot 1 od 6 ključnih spremenljivk pJIA če se je za definicijo poslabšanja uporabila globalna ocena zdravnika ali starša, je moralo biti prisotno poslabšanje za ≥ 2 cm (možno do 10 cm); če se je za definicijo poslabšanja uporabilo število aktivno prizadetih sklepov ali sklepov z omejeno gibljivostjo, je moralo biti prisotno poslabšanje pri ≥ 2 sklepih.
Remove the ClickJect Pre-filled Pen from the injection site by lifting it straight up. 
Odstranite ClickJect napolnjen injekcijski peresnik iz mesta injiciranja tako, da ga dvignete naravnost navzgor.
In a one-year toxicity study in cynomolgus monkeys, abatacept was not associated with any significant toxicity. 
Pri enoletni študiji toksičnosti na opicah cinomolgus niso odkrili pomembnejšega toksičnega delovanja abatacepta.
It is important that you tell your baby's doctors and other health care professionals about your ORENCIA use during your pregnancy before the baby receives any vaccine (for more information see section on vaccination). 
Pomembno je, da otrokovega zdravnika in drugo zdravstveno osebje, ki skrbi za otroka, obvestite o uporabi zdravila ORENCIA med nosečnostjo, preden otrok prejme katero koli cepivo (za več informacij glejte poglavje o cepljenju).
This medicinal product contains 34.5 mg sodium per maximum dose of 4 vials (8.625 mg sodium per vial), equivalent to 1.7% of the WHO recommended maximum daily intake of 2 g sodium for an adult. 
To zdravilo vsebuje 34,5 mg natrija na največji odmerek 4 viale (8,625 mg natrija na vialo), kar je enako 1,7 % največjega dnevnega vnosa natrija za odrasle osebe, ki ga priporoča SZO in znaša 2 g.
In people with rheumatoid arthritis the body's own immune system attacks normal body tissues, leading to pain and swelling of the joints. 
Pri bolnikih z revmatoidnim artritisom imunski sistem organizma napade normalna telesna tkiva, kar povzroči bolečino in oteklino sklepov ter lahko vodi do poškodbe sklepov.
In study II, the baseline median TSS was 31.7 in abatacept-treated patients and 33.4 in placebo-treated patients. 
V študiji II je bila srednja izhodiščna vrednost TSS pri bolnikih, ki so prejemali abatacept 31,7, pri bolnikih, ki so prejemali placebo, pa 33,4.
There was a significant improvement of DAS in studies II, III, V, and VI as compared to placebo or comparator. 
V študijah II, III, V in VI so opazili pomembno izboljšanje DAS v primerjavi s placebom ali primerjalnim zdravilom.
Component of a multipack, can't be sold separately. 
Del skupnega pakiranja, izdaja posamezne enote ni možna.
A. Choose an area of your body for the injection (injection site) You can use: o the front of your thigh o your abdomen, except for the 5 cm area around the navel (Figure 3). 
A. Izberite predel telesa, kamor si boste injicirali zdravilo (mesto injiciranja) Zdravilo si lahko injicirate pod kožo na: o sprednjem delu stegna o trebuhu, razen v predelu 5 cm okrog popka (slika 3).
At 12 months 61% (148/242) of the patients treated with abatacept plus methotrexate and 53% (128/242) of the patients treated with methotrexate plus placebo had no progression (TSS ≤ 0). 
Po 12 mesecih 61% (148/242) bolnikov, ki so se zdravili z abataceptom in metotreksatom, in 53% (128/242) bolnikov, ki so se zdravili z metotreksatom in placebom, ni imelo progresije (TSS ≤ 0).
Doctor's Name: ____________________ 
Ime in priimek zdravnika:
The incidence rate in abatacept-treated patients was 3.8 per 100 person-years in the cumulative period. 
V kumulativnem obdobju je stopnja pojavnosti pri bolnikih, ki so prejemali abatacept, znašala 3,8 na 100 bolnik-let.
Contact your doctor or pharmacist for assistance. 
Za pomoč se obrnite na svojega zdravnika ali farmacevta.
Anti-abatacept antibodies were generally transient and of low titer. 
Protitelesa proti abataceptu so bila v glavnem prehodna in nizkih titrov.
Table 8: 
Preglednica 8:
No evidence of lymphomas or preneoplastic morphological changes was observed, despite the presence of a virus, lymphocryptovirus, which is known to cause such lesions in immunosuppressed monkeys within the time frame of this study. 
V časovnem okviru študije niso opazili znakov limfomov ali preneoplastičnih morfoloških sprememb, kljub prisotnosti limfokriptovirusa, ki pri imunsko oslabljenih opicah dokazano povzroča tovrstne spremembe.
ORENCIA contains maltose, which is a type of sugar that can give falsely high blood glucose readings with certain types of blood glucose monitors. 
Zdravilo ORENCIA vsebuje maltozo, vrsto sladkorja, ki lahko pri uporabi nekaterih tipov merilcev krvnega sladkorja povzroči lažno visoke odčitke vrednosti krvnega sladkorja.
Abatacept was also evaluated in an open-label study in rheumatoid arthritis patients administered the seasonal influenza trivalent virus vaccine. 
Abatacept so vrednotili tudi v odprti študiji pri bolnikih z revmatoidnim artritisom, ki so prejeli trivalentno virusno cepivo proti sezonski gripi.
Abatacept was evaluated in an open-label study in rheumatoid arthritis patients administered the 23valent pneumococcal vaccine. 
Abatacept so vrednotili v odprti študiji pri bolnikih z revmatoidnim artritisom, ki so prejeli 23valentno cepivo proti pnevmokokom.
When the intravenous loading dose was not administered, a mean trough concentration of 12.6 mcg/mL was achieved after 2 weeks of dosing. 
Če začetni intravenski odmerek ni bil dan, je bila najmanjša koncentracija v stanju dinamičnega ravnovesja 12,6 μg/ml dosežena po 2 tednih zdravljenja.
Hold the syringe by its body in one hand, and pull the needle cover straight off with your other hand (Figure 4). 
Z eno roko primite injekcijsko brizgo za njeno telo, z drugo roko pa primite pokrovček igle in ga naravnost potegnite z igle (slika 4).
During Period B, the time to disease flare for the patients randomised to placebo was significantly shorter than for those randomised to abatacept (primary endpoint, p=0.0002; log-rank test). 
Med obdobjem B študije je bil čas do poslabšanja bolezni pri bolnikih, ki so bili randomizirani na placebo, pomembno krajši kot pri bolnikih, ki so bili randomizirani na abatacept (primarni izid, p=0,0002; log-rank test).
Step 4: Choose and Prepare an Injection Site Choose your injection site in either the abdomen, front of the thighs, or outer area of upper arm (only if caregiver administered). 
4. korak: Izbira in priprava mesta za injiciranje Izberite mesto injiciranja na trebuhu, sprednjem delu stegna ali zunanjem predelu nadlakti (le, če se zdravilo aplicira s pomočjo druge osebe).
The other ingredients are maltose, sodium dihydrogen phosphate monohydrate and sodium chloride (see section 2 "ORENCIA contains sodium"). 
Druge sestavine zdravila so maltoza, natrijev dihidrogenfosfat monohidrat in natrijev klorid (glejte poglavje 2 "Zdravilo ORENCIA vsebuje natrij").
*(e.g. pruritus, throat tightness, dyspnea) 
*(npr. srbenje, stiskanje v grlu, dispneja)
Less than 60 kg 
Manj kot 60 kg
if you become pregnant while using ORENCIA, tell your doctor. 
Če med zdravljenjem z zdravilom ORENCIA zanosite, to povejte svojemu zdravniku.
Patients achieving at least a ACR Pedi 30 response at the end of Period A were randomised into a double-blind, withdrawal phase (Period B), and received either abatacept or placebo for 6 months or until pJIA disease flare as defined in the study. 
Bolniki, ki so na koncu obdobja A dosegli odziv vsaj ACR Pedi 30, so bili randomizirani v dvojno slepo odtegnitveno fazo (obdobje B) in prejemali abatacept ali placebo 6 mesecev ali dokler se ni stanje pJIA poslabšalo kot je bilo določeno v študiji.
Summary of the safety profile in rheumatoid arthritis 
Povzetek varnostnega profila pri revmatoidnem artritisu
The overall safety profile was comparable between studies PsA-I and PsA-II and consistent with the safety profile in rheumatoid arthritis (Table 1). 
Celokupen varnostni profil je bil med študijama PsA-I in PsA-II primerljiv in skladen z varnostnim profilom pri revmatoidnem artritisu (preglednica 1).
Respiratory disorders occurred more frequently in abatacept-treated patients than in placebo-treated patients (10.8% vs. 5.9%, respectively); these included COPD exacerbation, and dyspnea. 
Bolezni dihal so bile pri bolnikih, ki so prejemali abatacept, pogostejše kot pri bolnikih, ki so prejemali placebo (10,8% v primerjavi s 5,9%), in so vključevale poslabšanje KOPB in dispnejo.
Once you remove it from your skin, the transparent tip will lock over the needle. 
Ko ga boste izvlekli iz kože, bo prozorna konica obdala in zavarovala iglo.
Keep track of your next dose. 
Vodite evidenco kdaj morate uporabiti naslednji odmerek.
If you do not respond well enough to these medicines, you may be given ORENCIA to: 
Če odziv na zdravljenje z drugimi zdravili ne bo zadosten, vam zdravnik lahko predpiše zdravljenje z zdravilom ORENCIA za:
Children weighing 75 kg or more should be administered ORENCIA powder for concentrate for solution for infusion following the adult dosing regimen. 
Otroci s telesno maso 75 kg ali večjo, morajo zdravilo ORENCIA prašek za koncentrat za raztopino za infundiranje prejeti v skladu z režimom odmerjanja za odrasle.
ORENCIA is used to: slow down the damage to joints improve physical function improve other signs and symptoms of polyarticular juvenile idiopathic arthritis 
Zdravilo ORENCIA uporabljamo za: upočasnitev napredovanja poškodb sklepov izboljšanje telesne zmogljivosti, izboljšanje drugih znakov in simptomov poliartikularnega juvenilnega idiopatskega artritisa.
Medicinal products that affect the immune system, including abatacept, may blunt the effectiveness of some immunisations. 
Zdravila, ki vplivajo na imunski sistem, vključno z abataceptom, lahko zmanjšajo učinkovitost nekaterih cepljenj.
There may be a little bleeding at the injection site. 
Na mestu injiciranja se lahko pojavi blaga krvavitev.
The safety and efficacy of intravenous ORENCIA in children below 6 years of age have not been studied and therefore, intravenous ORENCIA is not recommended for use in children under six years old. 
Varnosti in učinkovitosti intravenske uporabe zdravila ORENCIA pri otrocih, mlajših od 6 let, niso raziskovali, zato intravenska uporaba zdravila ORENCIA pri otrocih, mlajših od šest let, ni priporočljiva.
Age and gender (when corrected for body weight) did not affect apparent clearance. 
Starost in spol (če sta bila korigirana glede na telesno maso) nista vplivala na navidezni očistek.
Pull orange needle cover STRAIGHT off. 
Oranžni pokrovček igle potegnite NARAVNOST in ga odstranite.
However, if you are feeling tired or unwell after receiving ORENCIA, you should not drive or operate any machinery. 
Kljub temu pa v primeru, da se po prejemu zdravila ORENCIA počutite utrujeni ali se slabo počutite, ne smete voziti vozil ali upravljati s stroji.
Juvenile rats seemed to be more sensitive to lymphocytic inflammation of thyroid. 
Zdi se, da so bili mladiči podgan bolj dovzetni za limfocitna vnetja ščitnice.
ORENCIA has not been studied in these patient populations. 
Pri teh skupinah bolnikov uporabe zdravila ORENCIA niso raziskovali.
ORENCIA selectively modulates the activation of T cells involved in the immune system's inflammatory response. 
Zdravilo ORENCIA selektivno uravnava aktivacijo celic T. Celice T sodelujejo pri vnetnem odzivu imunskega sistema.
The overall safety profile was comparable between studies PsA-I and PsA-II and consistent with the safety profile in rheumatoid arthritis (Table 2). 
Celokupen varnostni profil je bil med študijama PsA-I in PsA-II primerljiv in skladen z varnostnim profilom pri revmatoidnem artritisu (preglednica 2).
You may use the same thigh for weekly injections, as long as each injection site is approximately 2.5 cm away from where you last injected. 
Zdravilo lahko vsak teden injicirate v isto stegno, vendar pa mora biti novo mesto injiciranja od predhodnega oddaljeno približno 2,5 cm.
Uncommon Palpitations, tachycardia, bradycardia 
Srčne bolezni občasni palpitacije, tahikardija, bradikardija